Twenty male patients with primary hypertriglyceridemia were treated for 4 weeks with daily supplements (15 g) of oil, which provided approximately 6 g of polyunsaturated fatty acid (PUFA) either of fish or of vegetable origin. Total plasma cholesterol concentrations were unaffected, but both types of supplement increased high density lipoprotein-3 (HDL 3 ) cholesterol concentrations. The fish, but not the vegetable, oil supplement led to a decrease in plasma triglyceride concentrations. Very low density lipoprotein (VLDL), fatty acid composition, and VLDL triglyceride kinetics were subsequently studied in five patients (four male, one female) before and after 4 weeks of therapy with 15 g of the same fish oil. The fish oil led to increases in the proportion of eicosapentaenoic acid in both the VLDL triglyceride and phospholipid fractions, but the increase was greater in the latter. In contrast, the proportion of docosahexanoic acid was increased only in the VLDL triglycerides. The decrease in plasma triglyceride concentrations that occurred with fish-oil therapy was accompanied by a reduction in the absolute catabolic rate of VLDL triglyceride, implying a concomitant change in synthetic rate; the fractional catabolic rate of VLDL triglyceride was unaltered. It is suggested that polyunsaturated fatty acids of marine origin may be therapeutically useful for hypertriglyceridemia.
H ypertriglyceridemia is the most prevalent form of hyperlipidemia in Western developed countries. It is associated with an increased risk of coronary heart disease, which is probably independent of its association with low plasma concentrations of high density lipoprotein (HDL) cholesterol in plasma. 1 Dietary modification plays an important role in the treatment of hypertriglyceridemia, 2 but the influence of dietary polyunsaturated fatty acids (PUFA) on plasma triglyceride and HDL cholesterol concentrations is variable. Dietary linoleic acid (18:2o>6) appears to have little effect on plasma triglyceride concentrations in normal 3 or hypertriglyceridemic subjects. 4 However, a marked reduction in plasma triglyceride and a slight increase in HDL cholesterol concentrations are seen in healthy subjects after the consumption of diets providing large amounts of oily fish 5 ' 6 or smaller amounts of fish oils 7 " 9 rich in eicosapentaenoic acid (20:5w3; EPA) and docosahexanoic acid (22:6a>3; DHA). A dose-response study 9 of a fish-oil supplement (MaxEPA, Seven Seas Health Care, Hull) showed that 10 g of this preparation was the minimum daily dose that had a significant triglyceride-lowering effect in healthy volunteers.
The purpose of the present study was to assess whether MaxEPA possessed a plasma triglyceridelowering effect of sufficient magnitude to be valuable in the clinical management of hypertriglyceridemia and, if so, to elucidate its mode of action.
Methods

Subjects
Twenty-one hypertriglyceridemic men attending the Lipid Clinic, Hammersmith Hospital, who consented to take part in the trial were randomly allocated into two groups to receive a daily supplement of either 15 g of fish oil (MaxEPA) or 15 g of a blend of corn and olive oils (Seven Seas Health Care, Hull). The allocation of treatments was double-blind, and the oils were provided in opaque, soft gelatin capsules each containing 1 g of oil. A peppermint flavor was added to both types of capsules to disguise the taste of the fish oil. On subsequent apo E phenotyping, one subject was found to have Type III hyperlipoproteinemia with the E2:E2 phenotype and was excluded from the results. The subjects were asked to stop taking all lipid-lowering drugs beginning 4 weeks before the start of the study. All the subjects had been previously advised to follow a modified-fat diet designed to achieve ideal body weight and to moderate their intake of alcohol; they were asked to maintain these constraints during the trial. Nine of the 20 subjects had previously been receiving lipidlowering drugs (clofibrate, hexopal, bradilan, or probucol; in the MaxEPA group the numbers of patients on those drugs were two, two, one, and one patients, respectively; in the vegetable-oil group, the numbers were two, zero, one, and zero, respectively). The remainder had received dietary advice alone. Every effort was made to keep non-lipid-lowering treatment stable during the period of investigation. The protocol and all procedures used were approved by the Research Ethics Committee, Royal Postgraduate Medical School, and informed consent was obtained in writing from all patients.
Experimental Procedures
The fatty-acid composition of the oils was determined by gas-liquid chromatography 8 with a 25 m fused silica capillary column coated with a chemically bonded OV-275 liquid phase at the start and the end of the study. Body weight was measured and venous blood samples were taken without stasis after an overnight fast at the start of the study and once again after the oil supplements had been administered for 4 weeks. Apo E phenotypes were determined on all subjects by isoelectric focusing. 10 Classification of the patients into lipoprotein phenotypes was made according to WHO criteria 11 on the basis of individual case histories. It was not possible to clearly classify some patients because their lipoprotein phenotypes had shifted from Type lib to Type IV and vice versa or from Type V to Type IV. Consequently, these patients were classified as llb/IV or IV/V. After ultracentrifugation of plasma at d = 1.006 g/ml in a Beckman 40.3 rotor at 40,000 rpm for 18 hours, total HDL 12 and HDL3 13 fractions were prepared from the infranatant and then frozen. The cholesterol concentration of the total HDL was determined by the Autoanalyzer I method as described by the Lipid Research Clinics Program; 14 that of the HDLg fraction was determined using the more sensitive o-pthalaldehyde method. 15 Total plasma cholesterol (C-system, Boehringer Corporation, Lewes, Sussex) and triglycerides (Human, Mercia Brocades, Byfleet, Surrey) were determined using enzymatic assays on frozen plasma. The same standards and quality control sera (Precimat and Precilip, Boehringer Corporation) were used for all assays. To gauge compliance to the oil supplement, the patients were requested to return any remaining capsules at the end of the study and capsule consumption was assessed. Compliance was also assessed by analyzing the fatty acid composition of the erythrocyte phosphoglycerides. 8 All assays were run in one batch to minimize between-assay variability.
Very low density lipoprotein (VLDL) composition and triglyceride kinetics were studied in a total of five patients (two male patients who were responders in the first trial and three additional hypertriglyceridemic patients, two male and one female). They were examined before and after 4 weeks of outpatient treatment with a daily supplement of 15 g of Max-EPA. The kinetic studies were carried out under metabolic ward conditions with a restricted fat intake (<5 g/day) and eucaloric diets; no fish oil supplements were given during the period of the VLDL turnover study. The diet consisted of 180 g of steamed white fish (0.25 g EPA and 0.32 g DHA), 600 ml of skimmed milk, 60 g of white bread, 15 g of cornflakes and 240 g of boiled potatoes. The balance of the energy intake was made up with carbohydrate foods to the number of calories habitually consumed by the patient as assessed by a dietitian. The same dietary regimen was followed by the patients in both kinetic studies. The kinetics of VLDL triglyceride 16 were studied by following its specific activity 48 hours after the injection of 100 /iCi 2-3 H-glycerol (Amersham International PLC, Bucks, United Kingdom). Plasma samples were collected at 0, 0.15, 2, 4, 6, 8, 10, 12, 18, 24, 30, 36, and 48 hours after injection of the labeled glycerol. VLDL were isolated in the d < 1.006 fraction following ultracentrifugation of the plasma in a Beckman 40.3 rotor at 40,000 rpm for 18 hours at 16° C. The specific activity of the VLDL triglycerides was determined after their selective extraction 17 by enzymatic assay of triglyceride and liquid scintillation counting of aliquots of the extract. For compositional studies, VLDL lipids were extracted with a chloroform-methanol mixture and separated by thin-layer chromatography; the VLDL triglyceride and phospholipid fractions were methylated with boron-fluoride reagent, and their fatty acid composition was determined by gas-liquid chromatography. 18
Statistical Analysis
A computer-assisted multicompartmental analysis of the VLDL kinetics data was performed by using the Nelder algorithm to obtain a least-squares fit of the linear, first-order, compartmental model of Zech et al. 19 Triglyceride concentrations and absolute catabolic rates were lognormalized before statistical analysis. A paired f test was used to compare differences before and after treatment, and an unpaired f test was used to compare the means of the differences before and after supplementation between treatments.
Results
Most of the patients had Type IV hyperiipoproteinemia, and many were overweight (>25) as reflected 
by the Quetelet Index (Table 1 ). In some instances their hypertriglyceridemia may have been exacerbated by other factors such as ingestion of alcohol or (3-blockers: five of the 11 subjects in the MaxEPA group and three of the nine in the vegetable-oil group were on R-blockers. Apo E phenotyping showed a higher prevalence of certain phenotypes, particularly the E4 phenotype, than would be expected from a group of men randomly selected from the general population. The prevalence of E4/E4, E3/E3, E4/E3, E4/E2 and E3/E2 phenotypes was 15%, 35%, 20%, 15%, and 15% in the patients compared with 3%, 55%, 26%, 3%, and 12% in the general population. 20 The MaxEPA oil contains a complex mixture of fatty acids (Table 2 ) but is notably low in gadoleic acid (20:1) and cetoleic acid (22:1) compared with other fish oils such as cod liver, herring, mackerel, and salmon oils, which contain approximately 10% to 20% by weight of these fatty acids. Both supplements provided similar amounts, but different types, of PUFA: the MaxEPA supplement provided 2.7 g EPA and 1.9 g DHA, whereas the vegetable-oil supplement provided 5.8 g of linoleic acid (the weight of total fatty acids in the oil was estimated by multiplying the weight of oil by a factor of 0.956 to allow for nonfatty acid components such as the glycerol backbone of the triglyceride molecule).
Compliance to both supplements appeared to be good, as assessed by capsule counts indicating that all the patients took more than 95% of the capsules. This conclusion was supported by the expected observation 8 that the proportion of EPA in the erythrocyte phosphoglycerides increased in the MaxEPAtreated group from 1.6 ± 0.18 wt% to 4.6 ± 0.22 (p < 0.01) after the supplement was taken, whereas there was no change in the vegetable-oil-treated group. As expected, 21 the proportion of linoleic acid in the erythrocyte phosphoglycerides was only slightly increased by use of the vegetable-oil-supplement from 11.9 ± 0.42 wt% to 12.4 ± 0.38 (p < 0.01). (Table 3) in the hypertriglyceridemic patients were low compared with values obtained in normolipidemic subjects assayed in the same laboratory (mean 1.3 ± 0.03 mmol/liter; 50 ± 1.2 mg/100 ml). Total HDL cholesterol concentrations tended to be greater following use of both supplements, although this was only statistically significant in the group that received the vegetable-oil supplement. The increase in HDL cholesterol concentration appeared to be due to an increase in the HDLg fraction. This fraction was signifi- Values are means ± SEM with number of subjects in parenthesis. Conversion to mg cholesterol/100 ml = mmol/liter x 38.5. Conversion to mg triglycerides/100 ml = mmol/liter x 88.5.
HDL cholesterol concentrations
*p < 0.05 for posttreatment vs pretreatment values, t p < 0.05 between treatments.
cantly greater after both types of treatment so that the HDL/HDL, cholesterol ratio was reduced; however, this was only statistically significant in the MaxEPA-treated group. There were no differences between treatments in concentrations of total cholesterol, or in HDL cholesterol, and its subtractions. Body weights also were unchanged. The two supplements differed markedly in their influence on plasma triglyceride concentrations. Plasma triglyceride concentrations fell in nine of the 11 subjects receiving the MaxEPA compared to three of nine receiving the vegetable-oil supplement ( Table 3 ). The change in plasma triglyceride concentrations in the four patients with "normal" E3/E3 apo E phenotypes averaged +0.58 ± 0.874 mmol/liter (51 ± 77.3 mg/100 ml), whereas in the remaining seven patients, all of whom had "abnormal" apo E phenotypes the change in triglyceride concentrations averaged -2 . 1 ± 0.405 (186 ± 35.8 mg/100 ml). One subject who did not respond to MaxEPA treatment reported heavy alcohol consumption the day before his post-supplement blood sample.
Details on the subjects who took part in the VLDL turnover study are shown in Table 4 . Table 5 shows that plasma triglyceride concentrations fell markedly in four of the five patients. During both metabolic ward studies, energy intakes for JF, MC, RS, VJ, and RH were 2040,1350,1350,1230 and 1480 kcal/day, respectively. Body weights were stable: the pre-MaxEPA weights were 77, 58, 77, 58, and 74 kg; the post-MaxEPA weights were 77, 58, 78, 58, and 74 kg, respectively. Plasma triglyceride concentrations Plasma triglyceride mean values reported in this table refer to the preceding 18 months and do not take into account changes in treatment that may have occurred during this time. Range is given in parentheses. See Table 3 for conversion formula. remained stable during both kinetic studies and there was no tendency for plasma triglyceride concentrations to rise after fish oil treatment. The plasma triglyceride concentration shown is the mean with standard deviation for all determinations made on each subject during the kinetic study. It is evident from this data that plasma triglyceride concentrations were stable. The plasma triglyceride-lowering effect was reproducible in the two patients (MC and RS) who received MaxEPA in the first trial. The data show values for MC to be: first trial, pre-MaxEPA 5.75 mmol (509 mg/100 ml) and post-MaxEPA 2.33 mmol/1 (206 mg/100 ml); second trial, pre-MaxEPA 6.00 mmol/liter (531 mg/100 ml) and post-MaxEPA 2.25 mmol/liter (199 mg/100 ml). The values for RS were: first trial, pte-MaxEPA 5.80 (mmol/liter (513 mg/100 ml); post-maxEPA 2.95 mmol/liter (261 mg/100 ml); second trial, pre-MaxEPA 8.00 mmol/ liter (708 mg/100 ml) and post-MaxEPA 4.15 mmol/ liter (455 mg/100 ml). Table 6 shows that the fatty acid composition of the VLDL was altered by treatment with MaxEPA, and the proportion of EPA in both the VLDL phospholipids and triglycerides increased, although this difference was more marked in the phospholipid fraction. This was accompanied by a reduction in the proportion of linoleic acid. The proportion of DHA (22:6<u3) was increased in the VLDL triglycerides, but not in the VLDL phospholipids. The reduction in plasma triglyceride concentration was accompanied by a substantial reduction in the absolute catabolic rate of VLDL triglyceride (which under steady-state conditions is equal to the synthetic rate) from 54.5 + 21.5 to 32.7 ± 13.5 /^mol/kg/hr. The fractional catabolic rate, however, was not altered (0.137 ± 0 . 1 2 compared with 0.148 ± 0.024 h r 1 after treatment). Values are means ± SEM. See Table 3 for conversion formula. *p < 0.05 for post-vs pretreatment period, t p < 0.01 for post-vs pretreatment period.
Discussion
The reduction in plasma triglyceride concentrations in the MaxEPA-treated group occurred despite a rise in plasma triglyceride concentrations in the vegetable-oil-treated group. This latter effect was probably due to a continuing washout effect following cessation of lipid-lowering drugs 4 weeks before the start of the trial. Our results showed that the fish-oil supplement was extremely effective in some patients but may have had no effect in others, possibly reflecting differences in the mechanisms causing their hypertriglyceridemia. Neither supplement affected total plasma cholesterol concentration, but this was to be expected because the amount of polyunsaturated fatty acids provided was small.
Hypertriglyceridemia results from an imbalance between the rate of production of triglyceride-rich lipoproteins and their clearance from the blood. A significant proportion of the polyunsaturated fatty acids derived from fish oil do circulate in VLDL; this, in turn, could influence its further metabolism. However, an increased rate of clearance of triglyceride from plasma seems an unlikely explanation for the effect of MaxEPA because HDL4 cholesterol concentrations did not rise and the fractional cataboiic rates did not change. Thus, the triglyceride-lowering effect of MaxEPA is almost certainly mediated by a decreased synthetic rate of VLDL triglyceride rather than by enhanced clearance. This is consistent with the recent report 22 of decreased VLDL apo B synthesis in humans and the observation that hepatic fatty acid synthesis is depressed in animals fed Max-EPA. 23 Nestel et al. 22 reported decreased VLDL triglyceride synthesis in two hypertriglyceridemic patients when the glycerol-labeling technique and much larger doses of MaxEPA were used. Our results demonstrate the same effect at lower doses. The observation that patients with apo E 4/4, 3/4, or 2/4 responded to the fish-oil supplement is of interest in view of the reported association between apo E phenotypes E4 and Type V hyperlipoproteinemia. 24 This suggests a genetic mechanism for hypertriglyceridemia in these patients and implies that the key to controlling hypertriglyceridemia is to limit the rate of VLDL triglyceride synthesis.
Our finding that HDL3 cholesterol concentrations were increased by both supplements illustrates that a rise in total HDL cholesterol does not necessarily reflect an increase in HDLj, cholesterol concentrations. Shepherd et al. 25 noted a reduction in total HDL cholesterol and a decrease in the ratio of HDLj/HDLj in normal subjects when the intake of polyunsaturated/saturated fat was increased from 0.25 to 4.0. In that study, the polyunsaturated fat was of vegetable origin. Other studies 7 " 9 have noted a slight increase in HDL cholesterol concentrations in normolipidemic subjects given fish-oil supplements but not in those given vegetable supplements. 9 x This discrepancy may reflect differences in HDL metabolism between normal and hypertriglyceridemic subjects. The mechanism for this increase in HDL cholesterol is not clear. However, it is well-documented 4 that bileacid output increases with fat intake and the degree of unsaturation of the dietary fat. Thus, the increase in concentration of HDLg cholesterol may be related to an increase in the enterohepatic circulation of bile acids, because compounds that interfere with the reabsorption of bile acids (for example, cholestyramine 27 ) lead to an increase in the ratio of HDLj/HDL, cholesterol. Coronary atherosclerosis is associated more closely with the cholesterol concentration in HDLg than with total HDL. 28 The pathophysiological significance of an increase in HDLj cholesterol concentration is uncertain.
The amounts of EPA and DHA provided by 15 g of MaxEPA oil were equivalent to those found 29 in about 200 g to 250 g of oily fish, such as mackerel or herring. This amount is similar to that consumed by some fish-eating populations, 30 but considerably less than the that consumed by Eskimos 31 or used in other studies of VLDL turnover. 22 Our results suggest that the partial substitution of modest amounts of marine oils for other fats in the diet through the consumption of seafood or fish-oil supplements is an efficient method of lowering plasma triglyceride levels in patients with primary hypertriglyceridemia associated with high rates of VLDL synthesis. In addition to reducing plasma triglyceride concentrations, such a change may also have a beneficial effect on the hemostatic function, 30 " 35 which has recently been reported 36 to be hyperactive in hypertriglyceridemia.
